1. Haas RH, Parikh S, Falk MJ, Saneto RP, Wolf NI, Darin N, et al. Mitochondrial disease: a practical approach for primary care physicians. Pediatrics 2007;120:1326-33.
2. Parikh S, Goldstein A, Koenig MK, Scaglia F, Enns GM, Saneto R, et al. Practice patterns of mitochondrial disease physicians in North America. Part 1: diagnostic and clinical challenges. Mitochondrion 2014;14:26-33.
3. Bhatia KD, Krishnan P, Kortman H, Klostranec J, Krings T. Acute cortical lesions in MELAS syndrome: anatomic distribution, symmetry, and evolution. AJNR Am J Neuroradiol 2020;41:167-73.
4. Bianchi MC, Tosetti M, Battini R, Manca ML, Mancuso M, Cioni G, et al. Proton MR spectroscopy of mitochondrial diseases: analysis of brain metabolic abnormalities and their possible diagnostic relevance. AJNR Am J Neuroradiol 2003;24:1958-66.
5. Hovsepian DA, Galati A, Chong RA, Mazumder R, DeGiorgio CM, Mishra S, et al. MELAS: monitoring treatment with magnetic resonance spectroscopy. Acta Neurol Scand 2019;139:82-5.
6. Lee HN, Yoon CS, Lee YM. Correlation of serum biomarkers and magnetic resonance spectroscopy in monitoring disease progression in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes due to mtDNA A3243G mutation. Front Neurol 2018;9:621.
7. Weiduschat N, Kaufmann P, Mao X, Engelstad KM, Hinton V, DiMauro S, et al. Cerebral metabolic abnormalities in A3243G mitochondrial DNA mutation carriers. Neurology 2014;82:798-805.
8. Bernier FP, Boneh A, Dennett X, Chow CW, Cleary MA, Thorburn DR. Diagnostic criteria for respiratory chain disorders in adults and children. Neurology 2002;59:1406-11.
9. Rehme AK, Eickhoff SB, Rottschy C, Fink GR, Grefkes C. Activation likelihood estimation meta-analysis of motor-related neural activity after stroke. Neuroimage 2012;59:2771-82.
10. Wu P, Zeng F, Li YX, Yu BL, Qiu LH, Qin W, et al. Changes of resting cerebral activities in subacute ischemic stroke patients. Neural Regen Res 2015;10:760-5.
11. Suomalainen A, Elo JM, Pietilainen KH, Hakonen AH, Sevastianova K, Korpela M, et al. FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study. Lancet Neurol 2011;10:806-18.
12. Tsujikawa T, Yoneda M, Shimizu Y, Uematsu H, Toyooka M, Ikawa M, et al. Pathophysiologic evaluation of MELAS strokes by serially quantified MRS and CASL perfusion images. Brain Dev 2010;32:143-9.
13. Niu FN, Meng HL, Chang LL, Wu HY, Li WP, Liu RY, et al. Mitochondrial dysfunction and cerebral metabolic abnormalities in patients with mitochondrial encephalomyopathy subtypes: evidence from proton MR spectroscopy and muscle biopsy. CNS Neurosci Ther 2017;23:686-97.
14. Li X, Wang Y, Wang Z, Lu J, Xu Y, Ye J, et al. Comparison of magnetic resonance spectroscopy (MRS) with arterial spin labeling (ASL) in the differentiation between mitochondrial encephalomyopathy, lactic Acidosis, plus stroke-like episodes (MELAS) and acute ischemic stroke (AIS). J Clin Neurosci 2018;55:65-70.
15. Maudsley AA, Andronesi OC, Barker PB, Bizzi A, Bogner W, Henning A, et al. Advanced magnetic resonance spectroscopic neuroimaging: experts' consensus recommendations. NMR Biomed 2021;34:e4309.